Axl inhibitor-mediated reprogramming of the myeloid compartment of the in vitro tumor microenvironment is influenced by prior targeted therapy treatment
Axl, a member of the receptor tyrosine kinase family comprised of Tyro3, Axl, and MerTK, is a promising cancer therapeutic target actively under clinical investigation. Axl is understood to be a dual target in cancer to (1) prevent tumor cell growth and invasion and (2) potentiate anti-tumor immunit...
Saved in:
| Main Authors: | Anisha Datta, Laura C. Bahlmann, Diana N. Gong, Erin N. Tevonian, James B. Lorens, Douglas A. Lauffenburger |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1601420/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dual targeting of TAM receptors Tyro3, Axl, and MerTK: Role in tumors and the tumor immune microenvironment
by: Kai-Hung Wang, et al.
Published: (2021-01-01) -
CD91-mediated reprogramming of DCs by immunogenic heat shock proteins requires the kinases AXL and Fgr
by: James Trey F. Harkness, et al.
Published: (2024-12-01) -
Human CD123+AXL+ dendritic cells express Siglec1 that captures and transmits HIV-1 particles to the T cells
by: Haisheng Yu, et al.
Published: (2025-06-01) -
AXL in myeloid malignancies – an elusive target?
by: Pia Aehnlich, et al.
Published: (2024-12-01) -
Analysis of Locomotive Axle Load Transfer with Considerationof Adhesive Force Varying for Each Axle
by: WEI Jia-qi, et al.
Published: (2014-01-01)